Loading
A phase 1/2 trial of Acalabrutinib, Rituximab, Lenalidomide in hodgkin lymphoma and non-hodgkin lymphoma, run by Acerta Pharma BV, active and no longer recruiting.
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT02180711 by Acerta Pharma BV, with 113 participants enrolled, started 2014-12-29 and due to reach its primary completion in 2023-08-25. Interventions recorded: acalabrutinib, rituximab (IV), Lenalidomide. Conditions listed: Non Hodgkin Lymphoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
113 enrolled.
95% CI 44.4 to 75.0; Figures from the ClinicalTrials.gov results section (first posted 2025-10-15), not from a publication · 95% CI 0 to 97.5
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Part 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL).primary | Part 2: Acalabrutinib | 43 | 60.5% | - | - | link |
| Part 2: Acalabrutinib + Rituximab | 1 | 0% |
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Lenalidomide, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.